Abstract
DNA methylation commonly occurs at cytosine-phosphate-guanine sites (CpGs) that can serve as biomarkers for many diseases. We analyzed whole genome sequencing data to identify DNA methylation quantitative trait loci (mQTLs) in 4,126 Framingham Heart Study participants. Our mQTL mapping identified 94,362,817 cis-mQTLvariant-CpG pairs (for 210,156 unique autosomal CpGs) at P<1e-7 and 33,572,145 trans-mQTL variant-CpG pairs (for 213,606 unique autosomal CpGs) at P<1e-14. Using cis-mQTL variants for 1,258 CpGs associated with seven cardiovascular disease risk factors, we found 104 unique CpGs that colocalized with at least one cardiovascular disease trait. For example, cg11554650 (PPP1R18) colocalized with type 2 diabetes, driven by a single nucleotide polymorphism (rs2516396). We performed Mendelian randomization (MR) analysis and demonstrated 58 putatively causal relations of CVD risk factor-associated CpGs to one or more risk factors (e.g., cg05337441 [APOB] with LDL; MR P=1.2e-99, and 17 causal associations with coronary artery disease (e.g. cg08129017 [SREBF1] with coronary artery disease; MR P=5e-13). We also showed that three CpGs, e.g., cg14893161 (PM20D1), are putatively causally associated with COVID-19 severity. To assist in future analyses of the role of DNA methylation in disease pathogenesis, we have posted a comprehensive summary data set in the National Heart, Lung, and Blood Institute’s BioData Catalyst.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Framingham Heart Study was supported by NIH contracts N01-HC-25195, HHSN268201500001I, and 75N92019D00031.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board for Human Research at Boston University Medical Center
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimer: The views and opinions expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute, the National Institutes of Health, or the U.S. Department of Health and Human Services.
Data availability: The datasets analyzed in the present study are available at the dbGAP repository phs000007.v32.p13.
Funding: The Framingham Heart Study was supported by NIH contracts N01-HC-25195, HHSN268201500001I, and 75N92019D00031. DNA methylation assays were supported in part by the Division of Intramural Research (D. Levy, Principal Investigator) and an NIH Director’s Challenge Award (D. Levy, Principal Investigator). The analytical component of this project was funded by the NHLBI Division of Intramural Research (D. Levy, Principal Investigator). Whole genome sequencing for the TransOmics in Precision Medicine (TOPMed) program was supported by the NHLBI. Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). J. Ma is supported by NIH grants, K22HL135075 and R01AA028263.
The authors’ contributions were as follows— DL and JM designed research, interpreted results, and had primary responsibility for final content; RJ and JM conducted the analyses; JM and RJ wrote the manuscript; HB contributed to the literature review used in the paper; CL AK, HS, HB, BT, MS, PJM, DYC, PC, NLH, ANP, MF, NS, RSV, and TH critically reviewed the manuscript; and all authors read and approved the final manuscript. The authors declare no conflicts of interest.
Summary data storage site has been updated.
Data Availability
All data produced are available online at dbGap
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000974.v4.p3
